Kivu Bioscience Inc. has released new preclinical efficacy and safety data on KIVU-107, a novel PTK7-targeting antibody-drug conjugate with a DAR4 exatecan payload. KIVU-107 is designed to be highly stable in circulation with negligible free payload release, maximizing on-tumor activity while minimizing off-target toxicity.
Suzhou Genhouse Bio Co. Ltd. has described histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of cancer, asthma, Alzheimer’s disease, diabetes, amyotrophic lateral sclerosis, multiple sclerosis, pulmonary fibrosis and psoriasis, among others.
Activating Toll-like receptors (TLRs) with agonists can promote pro-inflammatory responses mediated by the adaptor protein MyD88 and the downstream effector NF-κB, and these responses can inhibit tumor growth.
Beijing Chempion Biotechnology Co. Ltd. has synthesized antibody-drug conjugates comprising antibodies targeting folate receptor α (FOLR1; FR-α) covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.
While immunotherapy targeting PD-1 or its ligand PD-L1 has transformed cancer treatment by overcoming T-cell exhaustion, only a minority of patients achieves durable responses after treatment.
Allterum Therapeutics Inc. has obtained IND clearance from the FDA for 4A10, paving the way for initiation of a first-in-human phase I trial in patients with relapsed or refractory acute lymphoblastic leukemia (ALL). 4A10 is a monoclonal antibody with a human immunoglobulin G subclass 1 (IgG1) backbone that specifically binds to CD127 (IL-7Rα).
Tessera Therapeutics Inc. has been awarded up to $41.3 million from the Advanced Research Projects Agency for Health (ARPA-H) as part of its EMBODY (Engineering of immune cells inside the body) program to support the development of Tessera’s in vivo CAR T therapy efforts.
RSS
